BioMarin reports 5-year Pompe data showing durable motor function

• The combination therapy maintained motor function over five years of continuous treatment, helping patients preserve walking distance and respiratory stability
• Study included 82 patients, both treatment-naive and those previously on enzyme replacement therapy
• BioMarin acquired Amicus Therapeutics in December, expanding its presence in the rare metabolic disease space through this combination therapy

Summary

BioMarin Pharmaceutical announced positive five-year Phase 3 trial results for its combination therapy Pombiliti and Opfolda, used to treat late-onset Pompe disease (LOPD). The data was presented at the 31st annual World Muscle Society Congress in Japan.

Key Findings:

• The combination therapy helped adult patients maintain walking distance over five years of continuous treatment
• Respiratory function remained relatively stable throughout the long-term study period
• No new safety concerns were identified during the trial
• Study included 82 patients, comprising both enzyme replacement therapy (ERT)-naïve patients and those previously treated with ERT

Disease Background:

LOPD is a rare, inherited lysosomal disorder characterized by progressive muscle weakness throughout the body that worsens over time. The disease frequently affects respiratory muscles, impacting patients' ability to breathe.

Market Context:

In December, BioMarin acquired Amicus Therapeutics, which had been marketing this combination therapy. This strategic acquisition expanded BioMarin's portfolio in the rare metabolic disease space, strengthening its position in this specialized market segment.

Investment Implications:

The durable five-year efficacy data supports the long-term value proposition of BioMarin's Pompe disease franchise. Sustained motor and respiratory function without new safety signals strengthens the product's competitive position in the rare disease treatment landscape. The successful integration of the Amicus acquisition appears strategically sound, offering BioMarin enhanced exposure to the growing rare metabolic disease market with proven therapeutic assets.